Which TTR Silencers are available?

This directory covers 2: Onpattro, Amvuttra.

Transthyretin (TTR) Silencers

Also called RNAi therapies for amyloidosis, siRNA drugs

In hereditary transthyretin amyloidosis, a misfolded liver protein deposits in nerves and the heart. TTR silencers use RNA interference — a Nobel-winning mechanism — to destroy the messenger RNA for that protein before it is ever made, cutting circulating TTR by around 80%. Patisiran was the first RNAi drug ever approved; vutrisiran does the same job with an injection every three months instead of an infusion every three weeks.

What this class is used for

Hereditary transthyretin-mediated amyloidosis with polyneuropathy

2 TTR Silencers in this directory

Onpattro

Patisiran

An intravenous RNA interference therapy used to treat nerve damage caused by hereditary amyloidosis.

Amvuttra

Vutrisiran

An injectable RNA interference therapy administered every three months for hereditary amyloidosis neuropathies.

Compare TTR Silencers side by side

Onpattro VS Amvuttra

Browse other drug classes

ARBs Anti-amyloid Antibodies Antibiotics Antibody-drug Conjugates Anticoagulants Anticonvulsants Antihistamines Antiplatelets Asthma & COPD Inhalers Atypical Antipsychotics BTK Inhibitors Beta Blockers CD20 Antibodies CDK4/6 Inhibitors CGRP Inhibitors COVID-19 Antivirals Checkpoint Inhibitors Cholinesterase Inhibitors Complement Inhibitors DPP-4 Inhibitors EGFR Inhibitors Enzyme Replacement Therapy GLP-1 Agonists Gene & Cell Therapies HIV Antiretrovirals Hepatitis C Antivirals IL-1 Inhibitors IL-17 Inhibitors IL-23 Inhibitors IL-5 Inhibitors IL-6 Inhibitors Insulins JAK Inhibitors PARP Inhibitors PCSK9 Inhibitors Proton Pump Inhibitors SGLT2 Inhibitors SSRIs & SNRIs Statins TNF Inhibitors Tyrosine Kinase Inhibitors

Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons